醫療安全暨品質討論會 血品使用與急性反應處理
DESCRIPTION
醫療安全暨品質討論會 血品使用與急性反應處理. 朱芳業 臨床病理科主任 品質管理中心主任. (14:10~14:35 台大醫院第七講堂 ). 精神 誠勤樸慎 創新 宗旨 持續提升醫療品質 善盡社會醫療責任 願景 成為民眾首選的醫學中心. 大綱. 什麼時後該輸血 急性輸血反應之處置 結語. 案例. (TPR 通報案例 ). - PowerPoint PPT PresentationTRANSCRIPT
1
醫療安全暨品質討論會血品使用與急性反應處理
朱芳業臨床病理科主任 品質管理中心主任
(14:10~14:35 台大醫院第七講堂 )
精神 誠勤樸慎 創新宗旨 持續提升醫療品質 善盡社會醫療責任願景 成為民眾首選的醫學中心
2
大綱什麼時後該輸血急性輸血反應之處置結語
案例 病患因疑似輸血過敏呼吸喘 0:00AM ,停止輸血,通知值班醫師,予藥物 Solucortef 100mg IV → Brircayl 1Amp IH → Solu-medrol 40mg IV → Bosmin 3mg SC → Bricanyl IH 仍未改善,喘、 wheezing 重, ABG 呈酸中毒,經醫師評估予家屬解釋,預 on endo 緩解,並聯絡轉床
ICU 表示先於病房中 on 上 endo 後再轉,所以先 on endo ( 1AM 左右)。於 on endo 中, on 上時發現病人心搏變緩且至停止( 1AM30)故 call 9595 並予 2Am 轉床
病人血品( PRBC 2U )只輸約 150ml ,已請值醫 key 過敏通報,詢問血庫人員是否須將剩餘血品退回血庫檢驗,血庫人員表示應是白血球過敏,直接將剩餘血品丟掉即可
• 輸血 150 ml 呼吸喘,要懷疑什麼輸血反應,進行那些評估• Solucortef, Bricanyl, and Bosmin 是適當的處置嗎 ?• ABG 呈酸中毒, Ventilatory support 適當嗎 ?• 直接將剩餘血品丟掉恰當嗎 ?• 什麼是輸血過敏 ?
(TPR 通報案例 )
案例 A 81 year-old female 2012/08/02 14:45 Transfused 2U PRBC (CPD-SAGM) 2012/08/02 16:40 SOB, room air SPO2 79~86%, rales (+) developed
after transfusion of 320 ml of PRBC◦ Gave O2 mask 10 L/min, Furosemide 40 mg IV stat, Atrovent + Bricanyl
inhalation◦ CXR : Cardiomegaly
2012/08/03 14:45 ~ 16:27◦ Transfused 1U of LPR 2U and discarded the remaining 1U◦ Diphenylhydramine 30 mg IV stat before transfusion
2012/08/04 12:00 ~ 15:15◦ Transfused 1U of LPR 2U and discarded the remaining 1U◦ Furosemide 40 mg IV stat after transfusion
2012/08/04 23:11 SOB, four limbs edema I/O +700ml
• 血品的選用恰當嗎 ?• 輸血前給予 Diphenylhydramine 30 mg IV stat 是恰當的嗎 ?• 丟棄 1U LPR 是必要的嗎 ?
5
No TransfusionNo Transfusion
Reaction
Safe Transfusion : Processes Not Just Product
A+
Recruit
Screen donor
Collect & Process
TTD test
Product
Process
Pre-transfusion testing
Reason for Tx
Patient sample
Issue
AdministerMonitor
&Evaluate
(Adapted from Dzik, W. H. Hematology 2005;2005:476-482)
12 3
6
7
Reason for Transfusion
General Recommendations for Appropriate Hemoglobin Transfusion Thresholds
American Society of Anesthesiologists task force, 1996 British Committee for Standards in Haematology, 2001 Australian and New Zealand Society of Blood
Transfusion, 2001
Why transfusedIt Depends…Why not transfused
106
None of these guidelines recommended a specific transfusion trigger
7 8 g/dL
8
9
Red Blood Cell TransfusionA Clinical Practice Guideline From the AABB
Recommendation 1:The AABB recommends adhering to a restrictive transfusion strategy (7 to 8 g/dL) in hospitalized, stable patients(Grade: strong recommendation; high-quality evidence)
(Ann Intern Med. 2012;157:49-58.)
10
Red Blood Cell TransfusionA Clinical Practice Guideline From the AABB Recommendation 2:
The AABB suggests adhering to a restrictive strategy in hospitalized patients with preexisting cardiovascular disease and considering transfusion for patients with symptoms or a hemoglobin level of 8 g/dL or less(Grade: weak recommendation; moderate-quality evidence)
(Ann Intern Med. 2012;157:49-58.)
11
Red Blood Cell TransfusionA Clinical Practice Guideline From the AABB
Recommendation 3:The AABB cannot recommend for or against a liberal or restrictive transfusion threshold for hospitalized, hemodynamically stable patients with the acute coronary syndrome(Grade: uncertain recommendation; very low-quality evidence)
(Ann Intern Med. 2012;157:49-58.)
12
Red Blood Cell TransfusionA Clinical Practice Guideline From the AABB
Recommendation 4:The AABB suggests that transfusion decisions be influenced by symptoms as well as hemoglobin concentration(Grade: weak recommendation; low-quality evidence)
(Ann Intern Med. 2012;157:49-58.)
13
Comment Recent guidelines recommended a restrictive
strategy (transfusion when the hemoglobin level is less than 7 g/dL) for adult trauma and critical care patients, with the exception of those with acute myocardial ischemia
Avoiding transfusion based only on a hemoglobin trigger. Instead, the decision should be guided by such individual factors as bleeding, cardiopulmonary status, and intravascular volume
European Society of Cardiology has recommended : Withholding transfusion in patients with the ACS unless the hemoglobin concentration decreases to below 8 g/dL
Current Prophylactic Platelet Transfusion Thresholds (AABB)Patient Category Platelet Count
All patients 10,000/L
- or-
Stable patient 5,000/L
Patient with fever or recent hemorrhage (now stopped)
10,000/L
Patient with coagulopathy, on heparin, or with anatomic lesion likely to bleed
20,000/L
Note : These levels are most commonly applied to inpatient. Adjustment of the transfusion threshold may be necessitated by unusual clinical situations.
14
Although platelet source, ABO compatibility, and duration of storage exert a modest impact on both absolute and corrected posttransfusion platelet increments, they have no measurable impact on prevention of clinical bleeding.
(BLOOD 2012;119(23):5553-62)
16
What’s The Point? Current studies favor a restrictive
transfusion strategy More RCT for some clinical situations
17
急性輸血反應之處置
Adverse Effects of RBC Transfusion Contrasted with Other Risks
(Ann Intern Med 2012;157: 49-58. )18
19
Acute Complications Of Transfusion
Occur during or shortly after (within 24 hours) the transfusion
Broadly classified into three categories according to their severity and the appropriate clinical response
Guidelines for the Recognition & Management
of Acute Transfusion ReactionsCATEGORY SIGNS SYMPTOMS POSSIBLE CAUSE
CATEGORY 1 :
MILD REACTIONS
Localized cutaneous
reactions:
-Urticaria
-Rash
Pruritus (itching) Hypersensitivity (mild)
CATEGORY 2 :
MODERATELY SEVERE REACTIONS
Flushing
Urticaria
Rigors
Fever
Restlessness
Tachycardia
Anxiety
Pruritus (itching)
Palpitations
Mild dyspnea
Headache
Hypersensitivity (moderate-severe)
FNHTR:
Ab to WBC, PLT
Ab to proteins, including IgA
Possible contamination with pyrogens and/or bacteria
CATEGORY 3 :
LIFE-THREATENING REACTIONS
Rigors
Fever
Restlessness
Hypotension (fall of
≥20% in systolic BP)
Tachycardia (rise of
≥20% in heart rate)
Hemoglobinuria
(red urine)
Unexplained
bleeding (DIC)
Anxiety
Chest pain
Pain near infusion
site
Respiratory
distress/shortness
of breath
Loin/back pain
Headache
Dyspnoea
Acute intravascular hemolysis
Bacterial contamination and septic shock
Fluid overload (TACO)
Anaphylaxis
Transfusion-associated lung injury (TRALI)
20
Drugs that may be required in the management of acute transfusion reactionsTYPE OF DRUG RELEVANT
EFFECTEXAMPLES NOTES
Name Route and dosage
Intravenous replacement fluid
Expand blood volume
Normal saline If patient hypotensive, 20-30 ml/Kg over 5 minutes
Avoid colloid solutions
Antipyretic Reduce fever and inflammatory response
paracetamol Oral or rectal
10 mg/Kg
Avoid aspirin containing products if patient has low platelet count
Antihistamine Inhibit histamine mediated responses
Chlorpheniramine IM or IV
0.1 mg/Kg
Bronchodilator Inhibits immune mediated bronchospasm
Adrenaline
Consider salbutamol
Aminophylline
0.01 mg/Kg by slow IM injection
By nebulizer
5 mg/Kg
Dose may be repeated every 10 minutes according to blood pressure and pulse until improvement occurs
Inotrope Increases myocardial contractility
Dopamine
Dobutamine
IV infusion 1 g/kg/min
IVinfusion 1-10 g/kg/min
Dopamin in low doses induces vasodilation and improves renal perfusionDoes above 5 ug/kg/min cause vaso-constriction and worsen heart failure
Diuretics Inhibit fluid reabsorption from ascending loop of Henle
Frusemide Slow IV injection
1 mg/Kg
Platelets, Cryoprecipitate, Fresh frozen plasma
22
Key Recommendation Initial treatment of ATR is not
dependent on classification but should be directed by symptoms and signs. Treatment of severe reactions should not be delayed until the results of investigations are available. (1C)
23
Category 3 Life-threatening Reactions
Acute intravascular hemolysis Bacterial contamination and septic
shock Transfusion-associated circulatory
overload (TACO) Anaphylactic shock Transfusion-associated acute lung
injury (TRALI)
24
Category 3Life-threatening Reactions
Signs Rigors Fever Restlessness Shock Tachycardia Hemoglobinuria (red
urine) Unexplained
bleeding (DIC)
Symptoms Anxiety Chest pain Respiratory
distress/shortness of breath
Loin/back pain Headache Dyspnea
25
Transfusion-associated Circulatory Overload (TACO)
When too much fluid is transfused, the transfusion is too rapid or renal function is impaired, fluid overload can occur resulting in heart failure and pulmonary edema
Patients with chronic severe anemia, underlying cardiovascular disease, and infants are particularly at risk, especially during rapid transfusion
26
Transfusion-associated Circulatory Overload (TACO)
Management◦Stop the transfusion◦Administer O2 and diuretics as required
Prevention◦Avoid unnecessary fluids◦Use appropriate infusion rates◦Give diuretic before transfusion may be
required
27
Transfusion-associated Acute Lung Injury
TRALI is usually caused by donor plasma that contains antibodies against the patient’s leucocytes
Donors are almost always multiparous women
Usually presents within 1 to 4 hours of starting transfusion
Rapid failure of pulmonary function with diffuse opacity on the chest X-ray
28
Transfusion-associated Acute Lung Injury
Incidence◦In North America
Quebec 1/100,000-1/10,000 transfusions United States 1/5,000-1/1,323 transfusions
◦In Europe (rarer) 1.3/1,000,000-1/7,900 transfusions
◦True incidence remains unknown
Blood Reviews (2006) 20, 139–159
Definition of TRALI TRALI
◦ Acute onset◦ PaO2/FiO2 ≤ 300 or SpO2 < 90% on room air◦ Bilateral lung infiltrates on chest X ray◦ No evidence of left atrial hypertension◦ Occurrence during or within 6 hours of transfusion◦ No preexisting ALI before transfusion or temporal
relationship to an alternative ALI risk factor
Possible TRALI◦ In cases of TRALI occurring in the setting of transfusion
and an alternative risk factor for ALI◦ These alternative risk factors included a variety of
conditions that may directly or indirectly induce lung injury, such as pneumonia, pulmonary contusion, and sepsis.
(Canadian Consensus Conference Panel on TRALI, 2004 )29
30
Transfusion-associated Acute Lung Injury
Management◦No specific therapy - Intensive respiratory
and general support in an ICU is required◦Symptoms generally resolve over 24 - 48
hours Prevention
◦Diverting plasma units from multiparous women from the blood supply
Comparison of TRALI and TACOTRALI TACO
Patient characteristics More frequently reported in hematology and surgical patients
May occur at any age, but characteristically age > 70
Type of component Usually plasma or platelets Any
Speed of onset During or within 6 hours of transfusion, usually within 2 hours.
Defined as occurring within 6 hours of Transfusion
Oxygen saturation Reduced Reduced
Blood pressure Often reduced Often raised
JVP Normal Raised
Temperature Often raised Usually unchanged
CXR findings Often suggestive of pulmonary edema with normal heart size: may be a whiteout
Cardiomegaly, signs of pulmonary edema
Echo findings Normal Abnormal
Pulmonary wedge pressure
Low Raised
Full blood count May be fall in neutrophils and monocytes followed by neutrophil leucocytosis
No specific changes
Response to fluid load Improves Worsens
Response to diuretics Worsens Improves
32
Summary No transfusion no transfusion reaction Current studies favor a restrictive
transfusion strategy, though more RCT for some clinical situations
TACO and TRALI should be considered and treated as in patients developing respiratory distress during or shortly after transfusion
Management of ATRs is not dependent on classification but should be guided by symptoms and signs
33
Thanks for Your Attention !
jacpha@mail/femh.org.tw